TQB2450 with or without anlotinib as maintenance treatment in subjects with locally advanced/unresectable non-small cell lung cancer that have not progressed after prior concurrent/sequential chemoradiotherapy (R-ALPS): study protocol for a randomized, double-blind, placebo-controlled, multicenter phase III trial
TQB2450联合或不联合安罗替尼作为维持治疗，用于治疗既往接受过同步/序贯放化疗后未进展的局部晚期/不可切除的非小细胞肺癌患者（R-ALPS）：一项随机、双盲、安慰剂对照、多中心III期试验的研究方案
期刊:Translational Lung Cancer Research
影响因子:3.5
doi:10.21037/tlcr-24-362
Dong, Baiqiang; Chen, Long; Pang, Qingsong; Jiang, Ou; Ge, Hong; Cheng, Yufeng; Zhou, Rongrong; Meng, Xiangjiao; Li, Jie; Zhu, Xuan; Wang, Xunqiang; Cao, Qiuyue; Ji, Yongling; Chen, Ming
